Bharat Immunological & Biological Corporation quarterly results and financials

Bharat Immunological & Biological Corporation (BSE 524663)₹8.75+0.57%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Sep 2023 quarter (standalone), Bharat Immunological & Biological Corporation reported sales of ₹0 Cr, down 100.0% from Sep 2022, and net profit of −₹4.91 Cr. For the year to Mar 2023, sales were ₹45.16 Cr and net profit −₹16.98 Cr.

Sales (Sep 2023): ₹0 Cr
Net profit (Sep 2023): −₹4.91 Cr
Sales (FY Mar 2023): ₹45.16 Cr
Net profit (FY Mar 2023): −₹16.98 Cr
EPS (Sep 2023): ₹−1.13
Borrowings (Mar 2023): ₹69.95 Cr

Company filings, standalone accounts; latest reported quarter Sep 2023

Bharat Immunological & Biological Corporation quarterly results

₹ crore unless stated; each column is a quarter.

Bharat Immunological & Biological Corporation Quarterly results
	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023
Sales	25.26	15.67	14.26	24.75	17.49	22.08	10.50	26.54	0.00	7.68	0.00	0.00
Expenses	27.50	31.61	13.21	28.25	16.45	25.76	15.34	29.03	4.73	11.69	4.32	4.69
Operating Profit	−2.28	−15.93	1.05	−3.50	1.03	−3.68	−4.84	−2.49	−4.73	−4.03	−4.32	−4.69
OPM %	−9.0%	−101.9%	7.3%	−14.1%	5.9%	−16.6%	−46.1%	−9.4%	—	−52.5%	—	—
Other Income	1.19	9.06	0.24	0.21	0.11	0.58	0.13	0.31	0.09	0.48	0.09	0.15
Interest	1.29	1.21	1.15	1.22	1.53	1.67	1.59	1.73	1.66	2.05	1.71	2.08
Depreciation	0.05	0.05	0.05	0.05	0.03	0.04	0.03	0.03	0.03	0.08	0.02	0.02
Profit before tax	−2.42	−8.11	0.06	−4.55	−0.43	−4.80	−6.30	−3.95	−6.32	−5.67	−5.95	−6.63
Tax %	−21.9%	−19.5%	−2,642.9%	105.2%	−25.1%	−11.1%	−20.8%	−22.3%	−26.2%	−31.8%	−23.2%	−26.1%
Net Profit	−1.88	−6.52	1.92	−9.34	−0.32	−4.27	−4.99	−3.07	−4.67	−3.87	−4.58	−4.91
EPS (Rs)	−0.43	−1.50	0.44	−2.16	−0.07	−0.98	−1.15	−0.70	−1.07	−0.89	−1.05	−1.13

Bharat Immunological & Biological Corporation profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Bharat Immunological & Biological Corporation Profit and loss
	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Sales	173	203	146	128	124	35.10	84.18	67.21	85.26	78.16	45.16	7.68
Expenses	164	191	143	132	111	43.10	93.14	77.19	106	83.17	63.13	25.43
Operating Profit	9.01	12.01	3.01	−4.01	13.01	−8.01	−9.01	−10.01	−21.02	−5.01	−18.02	−17.77
OPM %	5.0%	6.0%	2.3%	−3.1%	10.0%	−23.0%	−11.0%	−16.0%	−24.0%	−6.0%	−40.9%	−231.4%
Other Income	0.99	5.98	0.99	0.99	0.99	0.99	3.99	0.99	1.99	0.99	2.99	0.81
Interest	1.99	5.99	0.99	5.99	3.99	0.99	1.99	4.99	4.99	5.99	6.99	7.50
Depreciation	0.99	0.99	0.99	0.99	0.99	0.00	0.00	0.00	0.00	0.00	0.00	0.15
Profit before tax	6.99	10.99	1.99	−8.99	8.99	−7.99	−6.99	−13.99	−23.97	−9.99	−22.98	−24.57
Tax %	27.0%	41.9%	26.0%	−31.1%	29.0%	−46.1%	−21.1%	−28.1%	−25.1%	−10.1%	−25.1%	—
Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Net Profit	4.99	5.99	1.99	−5.99	6.98	−3.99	−5.99	−9.98	−17.97	−8.98	−16.98	−18.03
EPS (Rs)	1.15	1.47	0.35	−1.43	1.50	−0.98	−1.33	−2.35	−4.18	−2.02	−3.94	−4.14
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—

Bharat Immunological & Biological Corporation balance sheet

₹ crore, at each year end.

Bharat Immunological & Biological Corporation Balance sheet
	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Equity Capital	42.82	42.81	42.85	42.86	42.82	42.88	42.87	42.84	42.83	42.87	42.87	42.88
Reserves	−14.99	−1.01	−2.99	−1.99	−8.01	−0.99	−5.99	−11.99	−22.99	−9.00	62.01	45.04
Borrowings	6.99	0.00	−0.99	−8.98	8.99	0.00	0.00	31.98	2.99	26.96	77.92	69.95
Other Liabilities	44.91	47.95	51.87	47.82	24.00	16.95	15.98	61.81	103	42.80	29.14	28.14
Total Liabilities	80.73	89.75	90.74	79.71	67.80	58.84	52.86	125	127	104	213	186
Fixed Assets	9.02	8.02	7.02	6.01	6.02	5.01	5.01	5.01	4.01	4.01	116	115
CWIP	0.99	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	31.93	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	70.72	81.73	83.72	73.70	62.78	52.83	47.85	120	122	67.69	96.66	69.74
Inventories	19.80	32.06	29.91	25.66	22.45	0.36	1.73	14.43	51.75	13.48	36.22	1.42
Trade receivables	26.65	1.09	26.27	13.74	13.13	6.47	15.98	73.20	17.66	0.02	1.14	13.92
Cash & equivalents	16.79	41.34	23.37	30.24	20.13	38.98	19.97	7.92	12.09	10.53	13.00	8.73
Total Assets	80.73	89.75	90.74	79.71	67.80	58.84	52.86	125	127	104	213	186

Bharat Immunological & Biological Corporation cash flow

₹ crore, for each year.

Bharat Immunological & Biological Corporation Cash flow
	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from operating activity	5.02	31.10	−12.03	8.02	−9.03	−17.05	3.01	−32.09	34.13	12.05	−42.17	11.03
Cash from investing activity	0.00	0.00	0.00	0.00	1.01	0.00	−0.99	1.01	1.01	1.01	1.01	0.00
Cash from financing activity	−3.01	0.00	−6.02	−1.01	−2.01	−3.01	−1.01	31.09	−34.10	−12.03	45.09	−15.03
Net cash flow	2.01	31.01	−18.01	7.01	−10.01	−20.03	1.01	−1.01	1.01	0.00	3.01	−3.01
Capex	0.00	0.48	0.05	0.27	0.09	0.43	0.00	0.02	0.00	0.00	0.00	0.00
Free cash flow	4.99	31.96	−11.99	7.99	−8.99	−16.99	2.99	−31.97	33.95	11.99	−41.96	10.98
CFO / OP %	89.1%	338.1%	−98.9%	229.1%	239.1%	−131.9%	−31.9%	344.0%	−328.0%	−55.9%	847.1%	−59.0%

Bharat Immunological & Biological Corporation ratios

Working-capital days and returns, by year.

Bharat Immunological & Biological Corporation Ratios
	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Debtor days	209	2	47	34	37	19	167	318	96	0	5	114
Inventory days	242	88	67	85	78	3	24	68	309	57	203	14
Days payable	316	99	70	103	26	1	6	204	259	61	5	4
Cash conversion cycle	135	−8	44	17	89	20	186	182	146	−4	204	123
Working capital days	−21	−21	20	19	27	−20	58	9	−109	−175	−228	−550
ROCE %	20.1%	23.0%	42.1%	9.1%	−7.9%	31.0%	−18.0%	−10.9%	−21.9%	−45.9%	−3.0%	−8.9%

Bharat Immunological & Biological Corporation: frequently asked questions

What are the latest quarterly results of Bharat Immunological & Biological Corporation?

For the Sep 2023 quarter, Bharat Immunological & Biological Corporation reported sales of ₹0 Cr, down 100.0% year on year and net profit of −₹4.91 Cr.

What is the annual revenue of Bharat Immunological & Biological Corporation?

Bharat Immunological & Biological Corporation's sales for the year to Mar 2023 were ₹45.16 Cr; over the last twelve months they were ₹7.68 Cr.

What is the net profit of Bharat Immunological & Biological Corporation?

Net profit for the year to Mar 2023 was −₹16.98 Cr, and −₹18.03 Cr over the last twelve months. Earnings per share over the same trailing period were ₹−4.14.

How much debt does Bharat Immunological & Biological Corporation have?

Bharat Immunological & Biological Corporation reported borrowings of ₹69.95 Cr at Mar 2023, against cash and equivalents of ₹8.73 Cr.

What is the free cash flow of Bharat Immunological & Biological Corporation?

Cash from operations was ₹11.03 Cr in the year to Mar 2023; after capital spending, free cash flow was ₹10.98 Cr.

Loading…